Abivax SA, a prominent biotechnology company headquartered in Paris, France, continues to make significant strides in the healthcare sector, particularly in the development of anti-viral therapies and therapeutic vaccines. As of January 5, 2026, the company’s stock, traded on the NYSE Euronext Paris, closed at €115, reflecting a dynamic year in terms of market performance. The share price has experienced considerable volatility, reaching a 52-week high of €128.40 on December 28, 2025, and a low of €4.51 on April 8, 2025. This fluctuation underscores the market’s response to both the company’s innovative pipeline and broader economic factors.
Abivax SA’s market capitalization stands at €9.38 billion, with a price-to-earnings ratio of -39, indicative of the company’s current phase of investment in research and development rather than profitability. The company’s focus remains on addressing infectious diseases prevalent in Asia and Latin America, leveraging its robust pipeline of products and partnerships.
The company’s flagship product, ABX 464, is in Phase II clinical trials and aims to provide sustained viral remission or a functional cure for HIV/AIDS patients. This candidate represents a significant advancement in the treatment landscape for HIV/AIDS, potentially offering long-term benefits to patients. Additionally, ABX 203, a therapeutic vaccine candidate for chronic hepatitis B, is progressing through Phase IIb/III trials, showcasing Abivax’s commitment to tackling chronic viral infections.
ABX 196, an art immune enhancer candidate, has completed Phase I clinical trials, focusing on iNKT cells, which play a crucial role in the immune response. This development highlights Abivax’s innovative approach to enhancing immune system functionality. The company also has a diverse portfolio of vaccines targeting typhoid, meningitis B and C, and leptospirosis, further demonstrating its broad impact on public health.
In the pre-clinical stage, Abivax is exploring ABX 220 for Dengue fever treatment, ABX 544, a polyclonal antibody-based candidate for Ebola, and ABX 311 for Chikungunya. These candidates reflect the company’s proactive stance in addressing emerging infectious diseases, particularly those with significant global health implications.
Strategic collaborations have been pivotal to Abivax’s progress. The company has established license contracts with the French National Centre for Scientific Research, the University of Montpellier 2 Science and Technology, and the Curie Institute. Additionally, a partnership with the Cuban Centro de Ingenia Genetica y de Biotecnologia underscores Abivax’s international reach and collaborative spirit.
Recent technical analysis of Abivax’s stock indicates a MACD Death Cross and narrowing Bollinger Bands, suggesting a potential shift in short-term momentum. While the stock is currently 10% below its 52-week high, it remains 25% above its 52-week low, indicating a relatively stable position within its historical volatility range. These technical signals may point to a tightening of market conditions, warranting close monitoring by investors.
In summary, Abivax SA continues to be a key player in the biotechnology sector, with a strong focus on developing innovative therapies for infectious diseases. The company’s strategic partnerships and diverse pipeline position it well for future growth, despite the inherent volatility in its stock performance. As Abivax advances its clinical trials and expands its product offerings, it remains a compelling entity within the healthcare landscape.
